Robert A. Parks was named Chief Accounting Officer of Guardant Health, Inc. As of November 6, 2026, Guardant Health, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 27, 2026 to November 3, 2026, naming 2 appointments (Form 8-K, November 3, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Guardant Health, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-03
- · In / out: In · Person: Kevin R. Sayer · Role: Director · Effective: 2026-11-02 · 8-K, 2026-11-03
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-27
Guardant Health, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-27 to 2026-11-03. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Guardant Health, Inc. files it.
Also on the record for Guardant Health, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 5.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 4.9% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 5.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by T. Rowe Price Associates, Inc. | 5.4% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.02% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Guardant Health, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Guardant Health, Inc. and the records around it.
Guardant Health, Inc. elsewhere on the record
Companies that share a holder
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Guardant Health, Inc.
Get an email when Guardant Health, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Guardant Health, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Guardant Health, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Guardant Health, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | Reported | not named in the filing | 8-K, 2026-11-03 | ||
| 2026-11-03 | In | Director | 2026-11-02 | 8-K, 2026-11-03 | |
| 2026-11-03 | In | Chief Accounting Officer | 8-K, 2026-11-03 | ||
| 2026-04-27 | Reported | not named in the filing | 8-K, 2026-04-27 |
Who leads Guardant Health, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Robert A. Parks, appointed (filed 2026-11-03).
- Director: Kevin R. Sayer, appointed, effective 2026-11-02 (filed 2026-11-03).
New leaders reset buying decisions — get the Full Report on Guardant Health, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Guardant Health, Inc., with the record behind each one.
Find candidates like Director at Guardant Health, Inc.Every change, in the filing's words
Reported
If the Co-CEO's employment terminates due to death or disability prior to the end of a performance period, the target number of PSUs for such performance period will vest.
- On November 2, 2026, the independent members of the Board of Directors (the "Board") of Guardant Health, Inc. (the "Company") approved the grant of performance-based restricted stock units ("PSU Awards") under the Company's 2018 Incentive Award Plan (the "Plan") to each of the Company's founders and Co-Chief Executive Officers, Helmy Eltoukhy and AmirAli Talasaz (the "Co-CEOs").
- Each Co-CEO received a grant of 465,413 PSUs at target (the "Target PSUs").
- These Target PSUs will only be eligible to be earned if the Company's total shareholder return ("TSR") relative to the constituents of the S&P 500 Index meets or exceeds certain performance requirements over three-year and five-year performance periods, as further described below.
- Driving Sustained Market-Leading Performance and Stockholder Value Creation Under the leadership of Drs.
- Eltoukhy and Talasaz, the Company delivered exceptional returns to stockholders as reflected in a total shareholder return of 275% over the last three fiscal years, outperforming the Nasdaq Biotechnology, Russell 3000 and S&P 500 indices over the same period.
- The PSU Awards are intended to align Co-CEOs' pay outcomes with the Company's sustained long-term value creation and incentivize market-leading performance over the next five years.
Appointed: Kevin R. Sayer, Director, effective 2026-11-02
On November 2, 2026, the Board of Directors (the "Board") of Guardant Health, Inc. (the "Company") increased the number of directors on the Board to 11 and appointed Kevin R. Sayer, 68, as a Class II director of the Company, to be effective as of November 2, 2026.
Appointed: Robert A. Parks, Chief Accounting Officer
On November 2, 2026, the Board appointed Robert A. Parks as Chief Accounting Officer and he assumed the role of principal accounting officer of the Company.
- Mr. Sayer will serve on the Board for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
- Mr. Sayer has served as a director on the board of Dexcom, Inc. since November 2007 and as Chairperson of the Board since July 2018.
- He was appointed Executive Chairman of the Board of Dexcom effective January 1, 2026.
- Mr. Sayer served as President and Chief Executive Officer of Dexcom from January 2015 to January 2026.
- From January 2013 until January 2015, Mr. Sayer also served as the company's Chief Operating Officer.
- From April 2007 to December 2010, Mr. Sayer served as Chief Financial Officer of Biosensors International Group, Ltd., a medical technology company developing, manufacturing and commercializing medical devices used in interventional cardiology and critical care procedures.
- Prior to joining Biosensors, Mr. Sayer served as an independent healthcare and medical technology industry consultant and in executive roles at Specialty Laboratories, Inc. a company offering clinical reference laboratory services, and MiniMed, Inc. until it was acquired by Medtronic, Inc. where he served in executive roles at Medtronic MiniMed.
Reported
On April 27, 2026, Guardant Health, Inc. (the "Company") announced the resignation of Craig Eagle, M.D., the Company's Chief Medical Officer, to be effective as of May 8, 2026.
Tools for this story
Each opens in a new tab, filled in for Guardant Health, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.